ŌURA Expands Menopause Impact Scale to Clinical Care via 10 Partner Integrations
Event summary
- ŌURA’s Menopause Impact Scale (MIS) is being integrated into clinical workflows via 10 partners across menopause care, primary care, telehealth, and hormone tracking.
- The MIS measures menopause’s impact on quality of life across 22 symptoms and 7 domains, validated with 2,900+ participants.
- Over 600,000 members have completed the MIS since its May launch, with 880,000+ completions recorded.
- Partners include Alloy Health, Oova, Xella, Pomelo, Wisp, Maven, Mira, Hertility, Gennev, and Tia, spanning virtual clinics, hormone tracking, and women’s health platforms.
The big picture
ŌURA’s move to integrate the MIS into clinical workflows aligns with the growing demand for personalized, data-driven menopause care. By creating a common measurement layer, ŌURA aims to standardize how menopause’s impact is tracked and managed across different care settings. This expansion could position ŌURA as a key player in the women’s health data ecosystem, particularly as more health platforms seek to incorporate longitudinal health metrics.
What we're watching
- Adoption Pace
- Whether the MIS can achieve widespread clinical adoption beyond ŌURA’s existing user base.
- Data Utilization
- How partners leverage MIS data to improve menopause care outcomes and longitudinal tracking.
- Competitive Positioning
- The extent to which ŌURA’s MIS differentiates it in the crowded women’s health tech space.